Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Q4 Adjusted EBITDA US$4.1 million and US$20.5 million cash

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Mar 18, 2022 7:32am

282 Views

Post# 34524468

RE:Q4 Adjusted EBITDA US$4.1 million and US$20.5 million cash

Very good numbers indeed especially product sales continuing to increase .

The only negative is the Absorica royalty continues to decline, despite the addition of AG.

It would seem that generics are having a signifucant impact on Absorica sales.
I don't see that changing although the bottom may have been reached.

Adding a new product to replace Absorica cash flows would seem to be the logical priority.

Otherwise, an excellent investment

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario